Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2020).
EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE..
J Cancer. 10(20), 4739-4746.
(2019). EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE ®.
Journal of Cancer. 10(20), 4739 - 4746.
(2019).
(2019). Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50..
Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
(2018). Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy..
Transl Lung Cancer Res. 7(Suppl 1), S46-S48.
(2018). Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?.
J Thorac Dis. 9(9), 2771-2773.
(2017). EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50..
Respir Med Case Rep. 22, 7-10.
(2017).